Diabetic nephropathy: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''diabetic nephropathies''', also called Kimmelstiel-Wilson Disease and glomerulosclerosis, are "kidney injuries associated with diabetes mellitus and affecting kidney gl...) |
imported>Paul Wormer No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[medicine]], '''diabetic nephropathies''', also called Kimmelstiel-Wilson Disease and glomerulosclerosis, are "kidney injuries associated with diabetes mellitus and affecting kidney glomerulus; arterioles; kidney tubules; and the interstitium. Clinical signs include persistent [[proteinuria]], from [[microalbuminuria]] progressing to [[albuminuria]] of greater than 300 mg/24 h, leading to reduced [[glomerular filtration rate]] and end-stage renal disease."<ref>{{MeSH}}</ref> | In [[medicine]], '''diabetic nephropathies''', also called Kimmelstiel-Wilson Disease and glomerulosclerosis, are "kidney injuries associated with diabetes mellitus and affecting kidney glomerulus; arterioles; kidney tubules; and the interstitium. Clinical signs include persistent [[proteinuria]], from [[microalbuminuria]] progressing to [[albuminuria]] of greater than 300 mg/24 h, leading to reduced [[glomerular filtration rate]] and end-stage renal disease."<ref>{{MeSH}}</ref> | ||
Revision as of 10:10, 6 September 2009
In medicine, diabetic nephropathies, also called Kimmelstiel-Wilson Disease and glomerulosclerosis, are "kidney injuries associated with diabetes mellitus and affecting kidney glomerulus; arterioles; kidney tubules; and the interstitium. Clinical signs include persistent proteinuria, from microalbuminuria progressing to albuminuria of greater than 300 mg/24 h, leading to reduced glomerular filtration rate and end-stage renal disease."[1]
Prevention
Telmisartan, an angiotensin II type 1 receptor blocker, slows the increase in albuminuria but may worsen the serum creatinine and glomerular filtration rate.[2]
References
- ↑ Anonymous (2024), Diabetic nephropathy (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Mann JF et al. TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. Epub 2009 May 18. PMID 19451556